- Home
- IINN vs NRSN Comparison
IINN vs NRSN Comparison
Compare IINN & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IINN
- NRSN
- Stock Information
- Founded
- IINN 2018
- NRSN 2017
- Country
- IINN Israel
- NRSN Israel
- Employees
- IINN N/A
- NRSN N/A
- Industry
- IINN Medical/Dental Instruments
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- IINN Health Care
- NRSN Health Care
- Exchange
- IINN Nasdaq
- NRSN Nasdaq
- Market Cap
- IINN 32.4M
- NRSN 29.8M
- IPO Year
- IINN 2021
- NRSN 2021
- Fundamental
- Price
- IINN $0.88
- NRSN $1.05
- Analyst Decision
- IINN Strong Buy
- NRSN Buy
- Analyst Count
- IINN 1
- NRSN 2
- Target Price
- IINN $2.00
- NRSN $14.00
- AVG Volume (30 Days)
- IINN 252.0K
- NRSN 202.5K
- Earning Date
- IINN 10-01-2025
- NRSN 12-17-2025
- Dividend Yield
- IINN N/A
- NRSN N/A
- EPS Growth
- IINN N/A
- NRSN N/A
- EPS
- IINN N/A
- NRSN N/A
- Revenue
- IINN $289,000.00
- NRSN N/A
- Revenue This Year
- IINN N/A
- NRSN N/A
- Revenue Next Year
- IINN $2,582.74
- NRSN N/A
- P/E Ratio
- IINN N/A
- NRSN N/A
- Revenue Growth
- IINN N/A
- NRSN N/A
- 52 Week Low
- IINN $0.40
- NRSN $0.80
- 52 Week High
- IINN $1.65
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- IINN 26.17
- NRSN 36.35
- Support Level
- IINN $1.01
- NRSN $1.03
- Resistance Level
- IINN $0.96
- NRSN $1.14
- Average True Range (ATR)
- IINN 0.06
- NRSN 0.08
- MACD
- IINN -0.02
- NRSN -0.01
- Stochastic Oscillator
- IINN 8.94
- NRSN 7.24
About IINN Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.